210421-71-9

Usage

Uses

Used in Water Treatment:
CMIT/MIT is used as a biocide in water treatment applications for its ability to inhibit the growth of microorganisms, thereby preventing biofouling and maintaining water quality. Its wide pH range effectiveness and low concentration requirements make it suitable for use in various water systems.
Used in Personal Care Products:
In the personal care industry, CMIT/MIT is used as a preservative to prevent microbial contamination in products such as cosmetics, lotions, and shampoos. Its broad-spectrum antimicrobial action helps ensure product safety and extends shelf life.
Used in Paints and Coatings:
CMIT/MIT is utilized as a microbicide in paints and coatings to prevent the growth of mold and mildew, which can cause discoloration and deterioration of the paint surface. Its effectiveness at low concentrations and wide pH compatibility makes it an ideal choice for various paint formulations.

InChI:InChI=1/C11H12ClN3O5S2/c1-6-8(12)10(20-13-6)14-22(17,18)7-4-5-21-9(7)11(16)15(2)19-3/h4-5,14H,1-3H3

Upstream product

• 59337-92-7 2-(carbomethoxy)thiophene-3-sulfonyl chloride 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 184040-74-2 3{[(4-chloro-3-methyl-5-isoxazolyl)amino]sulfonyl}-2-thiophenecarboxylic acid 

Downstream Products

• 184036-34-8 sitaxentan 

Relevant academic research and scientific papers

SITAXENTAN DERIVATIVE

A compound represented by formula (1-1) or (1-2), or a pharmacologically acceptable salt thereof retains the principal therapeutic effect of sitaxentan and has an improved CYP inhibitory effect: wherein R1 is a halogen atom, etc., R2 is a methyl group, etc., R3 is a C1-6 alkyl group, etc., and M is a group represented by: etc.

SUBSTITUTED THIOPHENES

Disclosed herein are substituted pyrimidine-based endothelin modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist

Previously we reported the discovery of amidothiophenesulfonamides as endothelin receptor-A antagonists with high potency and selectivity. Replacement of an amide group in this class of compounds with an acetyl group maintained the in vitro binding affinity and in vivo activity while providing a compound with oral bioavailability and longer duration of action. The optimal compound discovered during these studies, 15q (TBC11251), binds competitively to human ET(A) receptors with a K(i) of 0.43 ± 0.03 nM and an IC50 of 1.4 nM (IC50 for ET(B) = 9800 nM). This compound inhibits ET-1- induced stimulation of phosphoinositide turnover with a K(i) of 0.686 nM and a pA2 of 8.0. The compound has a serum half-life in the rat and the dog of 6-7 h and 60-100% oral bioavailability. This compound is one of the most selective ET(A) antagonists reported and therefore is suitable for additional pharmacological and clinical investigation of the role of ET(A) receptors in diseases.